康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06185 康希诺生物

未开盘 10-09 16:08:08

35.020

-0.940

-2.61%

最高36.960	最低34.020	成交量628.03万
今开36.340	昨收35.960	日振幅8.18%
总市值86.51亿	流通市值46.46亿	总股本2.47亿
成交额2.20亿	换手率4.73%	流通股本1.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":35.02,"timestamp":1791533288005,"preClose":35.96,"halted":0,"volume":6280290,"delay":0,"changeRate":-0.026140155728587255,"floatShares":132670900,"shares":247043801,"eps":0.12897775161859917,"marketStatus":"未开盘","change":-0.94,"latestTime":"10-09 16:08:08","open":36.34,"high":36.96,"low":34.02,"amount":219842578,"amplitude":0.081758,"askPrice":35.22,"askSize":400,"bidPrice":35.02,"bidSize":800,"shortable":3,"etf":0,"ttmEps":0.19287332977045318,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791768600000},"marketStatusCode":0,"adr":0,"listingDate":1553702400000,"exchange":"SEHK","adjPreClose":35.96,"openAndCloseTimeList":[[1791509400000,1791518400000],[1791522000000,1791532800000]],"volumeRatio":1.8625631825662987,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":98.46,"timestamp":1791529200000,"preClose":99.56,"halted":0,"volume":16111300,"delay":0,"premium":"-69.67"}},"requestUrl":"/m/hq/s/06185","defaultTab":"news","newsList":[{"id":"1192955614","title":"异动解读｜康希诺生物盘中下跌5.34%，莫德纳暴跌与获利回吐双重压制","url":"https://stock-news.laohu8.com/highlight/detail?id=1192955614","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192955614?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:39","pubTimestamp":1791509942,"startTime":"0","endTime":"0","summary":"10月9日，康希诺生物盘中下跌5.34%，报34.02港元，成交额3311.58万港元。消息面上，隔夜美股疫苗巨头莫德纳暴跌，加上花旗将莫德纳评级下调至卖出，负面情绪跨市场传导至港股疫苗及创新药板块。此前受ESMO年会数据预期提振，康希诺生物在国庆期间连续大涨，累计涨幅较大，短期获利盘回吐压力显著。康希诺生物股份公司是一家处于临床阶段的中国疫苗公司，产品主要应用于脑膜炎、百白破和肺炎领域，业务涵盖创新疫苗研发、生产及商业化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康希诺生物回调，莫德纳暴跌拖累情绪","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143555120","title":"异动解读｜康希诺生物盘中下跌5.21%，莫德纳暴跌拖累疫苗板块获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1143555120","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143555120?lang=zh_cn&edition=full","pubTime":"2026-10-08 15:27","pubTimestamp":1791444449,"startTime":"0","endTime":"0","summary":"10月8日，康希诺生物盘中下跌5.21%，报36.02港元，成交额3.77亿港元。隔夜美股疫苗巨头莫德纳暴跌8%，叠加花旗将莫德纳评级下调至卖出，情绪跨市场传导直接拖累港股疫苗及相关创新药板块。此前受益于ESMO年会数据预期，康希诺生物在国庆期间连续大涨，累计涨幅较大，短期获利盘回吐压力凸显。公司与德普世生物合作的mRNA个性化肿瘤疫苗仍处于早期开发阶段，市场对短期估值兑现趋于谨慎。康希诺生物股份公司是一家处于临床阶段的中国疫苗公司，产品主要应用于脑膜炎、百白破和肺炎领域，业务涵盖创新疫苗研发、生产及商业化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康希诺生物随莫德纳走弱，疫苗板块获利回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198325415","title":"康希诺生物更新2026年9月股份变动月报，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1198325415","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198325415?lang=zh_cn&edition=full","pubTime":"2026-10-07 16:43","pubTimestamp":1791362583,"startTime":"0","endTime":"0","summary":"康希诺生物股份公司于2026年10月7日发布截至2026年9月30日的股份变动月报文件。报告显示，康希诺生物本月未发生任何新增发行、股份购回或注销，整体股本规模保持稳定。根据公告，截至2026年9月30日，公司法定注册股本为人民币247,043,801元，其中包括132,670,900股H股与114,372,901股A股，总股本与上月保持一致，均无增减变动。公告强调，公司已遵守香港联合交易所有限公司的相关上市规则及其他法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190144897","title":"港股直击｜医药股及医药外包股重挫，金斯瑞生物科技大跌 14%，康希诺生物、歌礼制药跌 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190144897","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190144897?lang=zh_cn&edition=full","pubTime":"2026-10-07 09:38","pubTimestamp":1791337108,"startTime":"0","endTime":"0","summary":"医药股及医药外包股重挫，金斯瑞生物科技大跌 14%，昭衍新药跌 10%，康希诺生物、歌礼制药、再鼎医药、和铂医药跌 6%。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127","06185","01672","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180067981","title":"异动解读｜康希诺生物盘中下跌5.17%，ESMO催化退潮创新药板块普跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1180067981","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180067981?lang=zh_cn&edition=full","pubTime":"2026-10-07 09:34","pubTimestamp":1791336853,"startTime":"0","endTime":"0","summary":"10月7日，康希诺生物盘中下跌5.17%，报38.58港元，成交额1311.39万港元。此前受莫德纳ESMO数据预期推动，公司股价连续大涨，短期获利盘回吐压力显现。康希诺生物与德普世生物合作的mRNA个性化肿瘤疫苗仍处于早期开发阶段，市场对短期估值兑现趋于谨慎。康希诺生物股份公司是一家处于临床阶段的中国疫苗公司，产品主要应用于脑膜炎、百白破和肺炎领域，业务涵盖创新疫苗研发、生产及商业化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康希诺生物盘中下跌，ESMO退潮拖累创新药","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673803803","title":"港股异动 | 创新药概念股涨势延续 美银指近期三项重磅合作强化板块动能 ESMO有望带来密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2673803803","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673803803?lang=zh_cn&edition=full","pubTime":"2026-10-06 10:05","pubTimestamp":1791252333,"startTime":"0","endTime":"0","summary":"美银证券发布研报称，中国医药/生物科技近期三项合作强化板块动能渤海证券表示，近期AI制药催化密集，行业焦点逐步从模型能力转向湿实验验证效率等方面，建议关注AI制药相关基因合成、蛋白表达、试剂耗材、动物模型及临床试验等细分赛道的投资机遇。同时，2026年ESMO年会即将召开，优异临床数据有望读出，带来板块密集催化，建议关注创新药、CXO及生命科学上游产业链等的投资机遇。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2399975544.HKD","01177","LU0417516738.SGD","LU2778985437.USD","09926","LU2488822045.USD","06185","LU0417516902.SGD","IE00BZ08YR35.GBP","LU1961090484.USD","MEDX","HK0000165453.HKD","KCAI","IE00BPRC5H50.USD","LNGR","IE00BZ08YS42.EUR","LU1794554557.SGD","BK1161","LU0348784397.USD","LU0348766576.USD","BK1515","IE00B5MMRT66.SGD","LU0348783233.USD","BK4585","159992","BK1589","LU0348825331.USD","06978","LU0634319403.HKD","LU0540923850.HKD","LU2476274308.USD","VXUS","LU0348767384.USD","LU0417516571.SGD","KURE","IE00B543WZ88.USD","01672","IE00BZ08YT58.USD","LU2476274720.SGD","BK4588","LU0348735423.USD","LU0561508036.HKD","BK1191","BK1521","IBBQ","LU0348827113.USD","LU1720050803.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125826336","title":"异动解读｜康希诺生物盘中上涨8.65%，ESMO大会催化创新药估值重塑","url":"https://stock-news.laohu8.com/highlight/detail?id=1125826336","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125826336?lang=zh_cn&edition=full","pubTime":"2026-10-06 09:33","pubTimestamp":1791250406,"startTime":"0","endTime":"0","summary":"10月6日，康希诺生物盘中上涨8.65%，报38.8港元/股，成交额638.84万港元。消息面上，2026年欧洲肿瘤内科学会数据披露在即，中国药企参与占比达全球核心研究的1/3。公司正与德普世生物共同推进mRNA个性化肿瘤疫苗研发，已完成递送技术平台搭建并布局胶质母细胞瘤等适应症研究。行业分析认为，此次大会将提升国内创新药企全球价值链话语权，驱动中国肿瘤创新深度融入国际研发体系。康希诺生物股份公司是一家处于临床阶段的中国疫苗公司，产品主要应用于脑膜炎、百白破和肺炎领域，业务涵盖创新疫苗研发、生产及商业化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673771528","title":"部分医药股早盘高开 德琪医药-B涨超5%康希诺生物涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673771528","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673771528?lang=zh_cn&edition=full","pubTime":"2026-10-05 09:34","pubTimestamp":1791164040,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端部分医药股早盘高开，截至发稿，德琪医药-B（06996）上涨5.26%，报3.5港元；康希诺生物（06185）上涨3.58%，报35.88港元；昭衍新药（06127）上涨3.22%，报31.4港元；金斯瑞生物科技（01548）上涨2.93%，报45港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-05/doc-iniucpwr6623848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK1574","BK1191","BK1161","06996","BK1583","BK1515","06185","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673792787","title":"【券商聚焦】国金证券：行业有望迎业绩与估值戴维斯双击，创新药板块底部配置价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2673792787","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673792787?lang=zh_cn&edition=full","pubTime":"2026-10-05 08:50","pubTimestamp":1791161445,"startTime":"0","endTime":"0","summary":"随着后续管线商业化兑现、全球创新价值链话语权提升，行业有望迎来业绩与估值的戴维斯双击，创新药板块底部配置价值凸显。中国研究占全体大会核心LBA总量的1/3，这标志着中国肿瘤创新研发已深度融入全球研发体系，成为驱动全球肿瘤诊疗升级的重要力量，持续利好国内创新药企国际化发展与临床价值兑现。2026 ESMO已公布LBA标题，29项LBA的试验药物由中国药企原研或参与开发，涉及约20家企业，其中5项进入主席研讨会。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992996","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","02142","600109","IBBQ","LU0314109678.HKD","BK1610","BK1576","LU0516422952.EUR","01177","01093","LU1226288253.USD","LU0856984785.SGD","02269","BK0201","LNGR","06185","LU0211977185.USD","BK1515","KURE","02616","LU0823426308.USD","09688","LU0244354667.USD","LU0315179316.USD","BK1161","HK0000165453.HKD","LU0540923850.HKD","BK1583","01877","09995","LU2242644610.SGD","LU0052750758.USD","LU1226287875.USD","01801","KCE","LU2399975544.HKD","LU0455707207.USD","LU1328277881.USD","LU1807302812.USD","06160","159992","06978","LU0823426480.USD","LU1794554557.SGD","LU1242518931.SGD","LU0359202008.SGD","IE00BPRC5H50.USD","MEDX","IE0008368742.USD","LU0043850808.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167875004","title":"异动解读｜康希诺生物盘中下跌5.58%，连续大涨触发异常波动公告后回调承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1167875004","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167875004?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:48","pubTimestamp":1790905737,"startTime":"0","endTime":"0","summary":"10月2日，康希诺生物盘中下跌5.58%，报35.0港元/股，成交额1532.31万港元。消息面上，公司此前连续三个交易日收盘价涨幅偏离值累计超30%，已触发股票交易异常波动，公司公告强调不存在应披露而未披露的重大信息，董事及高管在异常波动期间未买卖公司股票。此前连续大涨主要受莫德纳mRNA新抗原疗法将亮相ESMO大会消息提振，叠加公司与德普世生物签署mRNA个性化肿瘤疫苗合作协议。当前生物科技板块整体走弱，百济神州跌6.65%、信达生物跌4.74%，短期获利回吐压力显现。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康希诺生物涨势暂歇，获利回吐压力显现","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133606776","title":"异动解读｜康希诺生物开盘下跌5.53%，连续大涨触发异常波动公告后回调承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1133606776","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133606776?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:21","pubTimestamp":1790904117,"startTime":"0","endTime":"0","summary":"10月2日，康希诺生物开盘下跌5.53%，报34.52港元/股，成交额89.75万港元。消息面上，公司此前连续三个交易日收盘价涨幅偏离值累计超30%，触发股票交易异常波动，已发布公告强调不存在应披露而未披露的重大信息，董事及高管在异常波动期间未买卖公司股票。此前连续大涨主要受莫德纳mRNA新抗原疗法将亮相ESMO大会消息提振，叠加公司与德普世生物签署mRNA个性化肿瘤疫苗合作协议。当前生物科技板块整体走弱，百济神州跌5.68%、信达生物跌3.93%，短期获利回吐压力显现。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康希诺生物回调承压，异常波动后获利盘涌出","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671058209","title":"康希诺生物(06185)A股股票交易异常波动 不存在应披露而未披露重大信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2671058209","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671058209?lang=zh_cn&edition=full","pubTime":"2026-09-30 19:51","pubTimestamp":1790769105,"startTime":"0","endTime":"0","summary":"公司关注到近期市场上关于 mRNA 技术的发展，海外mRNA肿瘤疫苗临床阶段性数据发布或计划公开。mRNA 平台是公司布局的技术平台之一，公司正在进行 mRNA 预防用疫苗及治疗性生物制品的开发，以及相关递送系统的开发。公司董事、高级管理人员、控股股东及其一致行动人在公司本次股票交易异常波动期间不存在买卖公司股票的情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03188","BK1191","02827","02823","BK1515","BK1610","159982","07233","02846","BK1574","83188","BK1147","83130","399300","82843","02822","03130","82823","06185","02843","BK1161","82822","82846"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134482661","title":"康希诺生物（06185）发布股票交易异常波动公告：三日累计涨幅偏离值超30%","url":"https://stock-news.laohu8.com/highlight/detail?id=1134482661","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134482661?lang=zh_cn&edition=full","pubTime":"2026-09-30 19:46","pubTimestamp":1790768777,"startTime":"0","endTime":"0","summary":"2026年10月1日，康希诺生物股份公司在上海证券交易所网站披露《股票交易异常波动公告》。公司股票在2026年9月28日、9月29日及9月30日连续三个交易日内日收盘价格涨幅偏离值累计超过30%，触及《上海证券交易所交易规则》及《上海证券交易所科创板股票异常交易实时监控细则》所列的“股票交易异常波动”情形。康希诺生物强调，董事、高级管理人员、控股股东及其一致行动人在股票异常波动期间不存在买卖公司股票的情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671222187","title":"AH股异动 | 康希诺生物A股涨停、H股大涨逾19%，莫德纳ESMO数据预期提振mRNA赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2671222187","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671222187?lang=zh_cn&edition=full","pubTime":"2026-09-30 13:25","pubTimestamp":1790745915,"startTime":"0","endTime":"0","summary":"消息面上，近日，美股疫苗概念股莫德纳公告，公司与默沙东联合开发的在研个体化mRNA新抗原疗法三项研究摘要，已获接收在10月23日至27日于马德里举行的2026年欧洲肿瘤内科学会大会上展示。据了解，康希诺已搭建mRNA开发和制备平台，公司旗下康希诺上海此前与德普世$生物$签署合作框架协议，共同开发mRNA个性化肿瘤疫苗，由康希诺提供mRNA递送及制剂能力，德普世提供AI新抗原发现和设计平台。","market":"fut","thumbnail":"https://community-static.tradeup.com/news/d019d7d8b494abffd2396b94314e7ea6","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/d019d7d8b494abffd2396b94314e7ea6"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502510.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"莫德纳ESMO数据预期提振mRNA赛道","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","03188","02843","BK1161","83188","159982","82843","KCAI","07233","82822","02822","BK1147","BK4585","02846","82823","03130","83130","BK1515","BK1574","BK4588","399300","06185","BK1610","82846","02823","02827","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671222053","title":"港股午评|恒生指数早盘跌0.04%    CRO概念股涨幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2671222053","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671222053?lang=zh_cn&edition=full","pubTime":"2026-09-30 12:00","pubTimestamp":1790740842,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数跌0.04%，跌10个点，报24513点；恒生科技指数跌0.15%。港股早盘成交887亿港元。mRNA概念股涨幅居前。CRO概念股涨幅居前，BD高增叠加湿实验需求升温，行业景气度上行信号明确。泰格医药涨超4%，与迪安诊断签署战略合作协议，将围绕AI制药等多领域开展深度合作。地产港股盘中V型反转，万科企业一度跌超11%，午盘涨超2%。汇量科技涨超8%，AI Infra升级有望进一步提升算法效率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02723","01787","GNOM","01164","LU0326950275.SGD","07500","03032","LGHT","02362","HK0000320264.USD","BK1574","09067","513600","BK1524","BK1521","HSTECH","HK0000306685.HKD","03347","BK1592","LU0463099449.HKD","82800","03037","000002","HSI","MCHmain","LU0244354667.USD","BK1576","BK4532","BK1137","03423","600547","BK1206","BK4501","BK1583","06185","MRNY","LU1831875114.USD","09088","03067","00625","BK1198","01860","BK4585","BK1544","BK4551","HHImain","03033","BK4534","HK0000320223.HKD","BK1161","BK4548","09115","03419","LU0181495838.USD","03115","LU0828237940.HKD","06127","BK4139","002821","BK1515","BK1590","BK4533","BK4568","07226","07300","02833","02202","MRNA","BK1507","06802","BK1240","300347","BK1141","BK1518","IDNA","BK1555","BK4588","URNJ","BK1178","WDNA","BK1594","BK1613","688185","IE0034224299.USD","01548","07200","07552","BK1191","LU1188198961.HKD","LU0140636845.USD","MRNX","83115","02800","BK1586","03088","603127","03417","HK0000306701.USD","06821","02837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671225002","title":"A股午评：沪指早间涨0.27%，超2300只个股上涨，房地产股探底回升","url":"https://stock-news.laohu8.com/highlight/detail?id=2671225002","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671225002?lang=zh_cn&edition=full","pubTime":"2026-09-30 11:35","pubTimestamp":1790739354,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06185","BK0053","600663","BK0273","LU0072913022.USD","LU1655091616.SGD","LU0880133367.SGD","03147","BK0188","BK0201","LU0501845795.SGD","07234","000001","BK0196","BK0239","LU1993786604.SGD","688185","LU1781817850.SGD","BK0184","399006","IE00B0JY6N72.USD","LU1226287529.USD","LU1580142542.USD","LU0067412154.USD","BK0011","BK0020","BK0278","BK0012","BK0028","BK0187","BK0183","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113488989","title":"港股直击｜生物医药股及医药外包股飙升，康希诺生物大升18%，金斯瑞生物科技升8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113488989","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113488989?lang=zh_cn&edition=full","pubTime":"2026-09-30 09:55","pubTimestamp":1790733300,"startTime":"0","endTime":"0","summary":"生物医药股及医药外包股飙升，康希诺生物大升 18%，金斯瑞生物科技升 8%，昭衍新药升 7%，云顶新耀、药明巨诺升 6%。","market":"hk","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548","06127","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671822138","title":"港股异动 | mRNA概念股涨幅居前 康希诺生物(06185)涨超17% 莫德纳mRNA新抗原疗法将亮相ESMO大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2671822138","media":"智通财经","labels":["productRelease","conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671822138?lang=zh_cn&edition=full","pubTime":"2026-09-30 09:47","pubTimestamp":1790732842,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，mRNA概念股涨幅居前，截至发稿，康希诺生物涨16.78%，报36.32港元；云顶新耀涨4.29%，报29.18港元；思路迪医药股份涨1.94%，报2.89港元；剂泰科技-P涨1.44%，报16.22港元。值得注意的是，8月25日，康希诺生物与德普世生物签署《mRNA个性化治疗型肿瘤疫苗共同开发战略合作框架协议》。此前在mRNA领域，康希诺生物已布局mRNA 疫苗用于胶质母细胞瘤、横纹肌肉瘤及宫颈癌等适应症的研发。云顶新耀计划在2026年第四季度开展对mRNA疫苗EVM16的 IIT Ib研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK4588","VXUS","01244","06185","BK1161","BK1574","BK4585","07666","KCAI","BK1583","01952","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185246668","title":"异动解读｜康希诺生物盘中上涨5.92%，mRNA肿瘤疫苗合作主题持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1185246668","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185246668?lang=zh_cn&edition=full","pubTime":"2026-09-30 09:34","pubTimestamp":1790732085,"startTime":"0","endTime":"0","summary":"9月30日，康希诺生物盘中上涨5.92%，报34.18港元/股，成交额3162.51万港元。消息面上，公司此前宣布子公司康希诺上海与德普世生物签署mRNA个性化治疗型肿瘤疫苗共同开发战略合作框架协议，聚焦消化道实体瘤及罕见肿瘤领域。里昂研报指出，康希诺mRNA开发路线与Moderna大致相若，属平台级别估值重估机会。此外，交银国际认为中国内地mRNA疫苗产业整体低估严重，Moderna黑色素瘤III期研究达主要终点有望推动板块估值修复。该股近期围绕mRNA合作主题反复活跃，节后延续反弹态势。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物盘中上涨，mRNA肿瘤疫苗合作持续发酵","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671266951","title":"康希诺生物（688185）9月28日主力资金净买入6635.44万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671266951","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671266951?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:17","pubTimestamp":1790641025,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，康希诺生物报收于86.5元，上涨5.99%，换手率9.1%，成交量10.4万手，成交额8.9亿元。近5日资金流向一览见下表：康希诺生物融资融券信息显示，融资方面，当日融资买入8488.95万元，融资偿还7080.37万元，融资净买入1408.58万元。康希诺生物主营业务：创新疫苗的研发、生产及商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900006987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","06185","BK1191","BK1161","BK0239","688185","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cansinotech.com","stockEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.2219},{"period":"3month","weight":0.4953},{"period":"6month","weight":0.0696},{"period":"1year","weight":-0.2862},{"period":"ytd","weight":0.0029}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":-0.0421},{"period":"3month","weight":0.0015},{"period":"6month","weight":-0.065},{"period":"1year","weight":-0.095},{"period":"ytd","weight":-0.0554}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.030578},{"month":2,"riseRate":0.857143,"avgChangeRate":0.172684},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.060436},{"month":4,"riseRate":0.625,"avgChangeRate":0.049828},{"month":5,"riseRate":0.25,"avgChangeRate":-0.051769},{"month":6,"riseRate":0.5,"avgChangeRate":0.015607},{"month":7,"riseRate":0.625,"avgChangeRate":0.054796},{"month":8,"riseRate":0.25,"avgChangeRate":-0.091996},{"month":9,"riseRate":0.75,"avgChangeRate":0.089616},{"month":10,"riseRate":0.375,"avgChangeRate":0.046577},{"month":11,"riseRate":0.571429,"avgChangeRate":0.088604},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.035813}],"exchange":"SEHK","name":"康希诺生物","nameEN":"CANSINOBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺生物,06185,康希诺生物股票,康希诺生物股票老虎,康希诺生物股票老虎国际,康希诺生物行情,康希诺生物股票行情,康希诺生物股价,康希诺生物股市,康希诺生物股票价格,康希诺生物股票交易,康希诺生物股票购买,康希诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}